The New England Journal of Medicine recently published three randomized, double-blind, placebo-controlled trials of Truvada for use as pre-exposure prophylaxis in men and women.  Two of the 3 studies found that once-daily oral Truvada correlates with risk reductions against HIV infection. Although there were limitations to these studies, advocates for AIDS prevention are urging the FDA to approve Truvada for this new indication.  If approved, critics fear that the drug will reduce the use of condoms. What are your thoughts on this matter?,0,3763131.story?track=rss&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+latimes%2Ffeatures%2Fhealth+%28L.A.+Times+-+Health%29&utm_content=Google+Reader